regardless of promising clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing website considerable opposition from PBMs. These insurers are frequently creating barriers to reimbursement, including steep expense criteria and prior authorization that restrict patient availability. Marke